Affiliation:
1. Federal State Autonomous Educational Institution of Higher Education “N. I. Pirogov Russian National Research Medical University” of the Ministry of Health of Russia
2. Federal State Autonomous Educational Institution of Higher Education “N. I. Pirogov Russian National Research Medical University” of the Ministry of Health of Russia ; GBUZ “Kommunarka Moscow Multidisciplinary Medical Center” of Moscow Healthcare Department
Abstract
Objective: To evaluate clinical and microbiological effectiveness of the combined preparation Simprazole® (ornidazole 500 mg + ciprofloxacin 500 mg) in patients with skin and soft tissue infections.Material and methods. This prospective study was conducted in a multidisciplinary hospital from February to May 2023. Outcomes after treating patients with purulent wounds of the skin and soft tissues of various origins and location were analyzed. Patients with the extremely severe infectious processes and decompensated diseases of cardiopulmonary, respiratory and other vital systems were excluded from the study. Resistance and sensitivity of isolated strains to antibiotics was assessed in patients’ tests in 7 or 14 days. Patients with strains sensitive to ciprofloxacin were enrolled in the study. In addition to the antibacterial therapy, they had local treatment (dressings and wound debridement).Results. The involved 60 patients had a combined surgical treatment in the hospital. Clinical and laboratory findings have shown that the combined preparation consisting of ciprofloxacin and ornidazole has a high clinical and bacteriological effectiveness (95 and 96.7 %, respectively) in patients with purulent wounds of the skin and soft tissues regardless of pathogens etiology (aerobic or anaerobic) and anaerobic component, if these pathogens are sensitive to ciprofloxacin. The discussed preparation is well tolerated in 99 % of cases; no registered adverse reactions.Conclusion. The combined preparation Simprazole® (500 mg of ornidazole and 500 mg of ciprofloxacin) has a wide spectrum of action and original mechanisms of impact at microbes. It is an effective and safe drug for treating skin and soft tissue infections from both clinical and microbiological points of view.
Publisher
RPO Surgical Society - Wound and Wound Infections
Reference18 articles.
1. Fedyanin S. D., Kosinets V. A., Khrustalev B. M. i dr. Primenenie apparata dlya vakuumnoi terapii Impul's KM-1 v kompleksnom lechenii khirurgicheskikh infektsii kozhi i myagkikh tkanei. Vestnik Natsional'nogo mediko-khirurgicheskogo tsentra im. N. I. Pirogova. 2021; 16 (2): 72–76. [Fedyanin S. D., Kosinets V. A., Khrustalev B. M., et al. Use of the device for vacuum therapy Impulse KM-1 in the complex treatment of surgical infections of the skin and soft tissues = Fedyanin S. D., Kosinets V. A., Khrustalev B. M. i dr. Primeneniye apparata dlya vakuumnoy terapii Impul’s KM-1 v kompleksnom lechenii khirurgicheskikh infektsiy kozhi I myagkikh tkaney. Vestnik Natsional’nogo mediko-khirurgicheskogo tsentra im. N. I. Pirogova. 2021; 16 (2): 72–76. (In Russ.)]
2. Alverdy J. C., Hyman N., Gilbert J. Re-examining causes of surgical site infections following elective surgery in the era of asepsis. Lancet Infect Dis. 2020; 20 (3): e38–e43.
3. Kolasiński W. Surgical site infections – review of current knowledge, methods of prevention. Pol Przegl Chir. 2018; 91 (4): 41–47.
4. Profilaktika infektsii oblasti khirurgicheskogo vmeshatel'stva: klinicheskie rekomendatsii. N. Novgorod: Izd-vo «Remedium Privolzh'e», 2018. 72 s. [Prevention of surgical site infections: clinical recommendations = Profilaktika infektsiy oblasti khirurgicheskogo vmeshatel’stva: klinicheskiye rekomendatsii. N. Novgorod: Izd-vo «Remedium Privolzh’ye», 2018. 72 s. (In Russ.)]
5. Berríos-Torres S. I., Umscheid C. A., Bratzler D. W., et al. Centers for Disease Control and Prevention Guideline for the Prevention of Surgical Site Infection, 2017. JAMA Surg. 2017; 152 (8): 784–791.